Biotech Firm Arcellx Acquired for $26 Million Amid Stock Underperformance and Competition

Biotech company Arcellx has been sold for $26 million, following a period of weak stock performance and increasing competition from rivals like Kelonia.

17 Feb, 18:07 — 17 Feb, 18:07